BioPharma Dive May 10, 2021
Activation strategies are needed to reduce patient diagnostic delay
Finding HCPs who are managing yet-to-be-diagnosed patients with rare diseases is often said to be analogous to finding a needle in a haystack. A better analogy would be mining for gold; knowing where to dig is only half the problem. The strategy for bringing this value to the surface is another matter.
Identifying the HCPs who have undiagnosed rare disease patients tells us where to dig, however we need to “bring this value to the surface”. Simply identifying HCP’s having rare disease patients will not alter the rate at which these patients are diagnosed. The delay period between symptom onset and correct diagnosis is not generally correlated with AI-model scores....
Today's Sponsors
Today's Sponsor